SIOC 中文
CJOG
Adv search

Chinese Journal of Organic Chemistry >

2019 , Vol. 39 >Issue 10: 2958 - 2964

DOI: https://doi.org/10.6023/cjoc201903020

NOTES

Synthesis and Anti-inflammatory Effects of Oxaprozin-Paeonol Ester

  • Xuetao Xu, ,
  • Jie Chen, ,
  • Zhiqing Lin, ,
  • Dongli Li, ,
  • Kun Zhang, ,
  • Zhaojun Sheng, ,
  • Shaohua Wang, ,
  • Shun Zhu, ,
  • Asiri Abdullah M.
Expand
  • a School of Biotechnology and Health Sciences, Wuyi University, Jiangmen 529020, Guangdong, China
    b School of Pharmacy, Lanzhou University, Lanzhou 730000, China
    c Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co., Ltd., Changzhou 213100, Jiangsu, China

Received date: 2019-03-12

  Revised date: 2019-05-15

  Online published: 2019-05-21

Supported by

Project supported by the Department of Education of Guangdong Province(2017KTSCX185);Project supported by the Department of Education of Guangdong Province(2017KSYS010);Project supported by the Department of Education of Guangdong Province(2016KCXTD005);the Youth Team Fund of Wuyi University(2016td01);the National Natural Science Foundation of China(Nos. 21472077);the National Natural Science Foundation of China(21772071)

Fold

Abstract

Oxaprozin is a common anti-inflammatory drug in the clinic. Oral medication of oxaprozin potentially induces the GI perforation, which is caused by the local irritation of its carboxylic acid group. Paeonol is an active ingredient of peony, and has anti-inflammatory and anti-oxidant effects. So oxaprozin-paeonol ester (OPE) was designed to avoid the GI complications and enhence corresponding anti-inflammatory. The topical anti-inflammatory effects of OPE was evaluated in a 12-O-tetradecanoylphorbol-13-acetate (TPA) induced mouse ear edema model. The results showed that topical treatment of OPE could effectively improve the TPA-induced ear edema and its anti-inflammatory effect is 2 times higher than that of oxaprozin and 4 times than that of paeonol. Moreover, OPE treatment could effectively mitigate the expression of IL-1β, IL-6, and TNF-α, and its effect is better than that of oxaprozin or paeonol. Furthor study demonstrated that topical treatment of OPE could obviously down-regulate the activation of factor kappa-κB (NF-κB) by blocking IκB kinase (IKK) activities. Accordingly, OPE might be used as a promising anti-inflammatory agent for inflammation-associated skin diseases.

Key words： Oxaprozin; Paeonol; Inflammatory; Ear edema mode

Cite this article

Xuetao Xu, , Jie Chen, , Zhiqing Lin, , Dongli Li, , Kun Zhang, , Zhaojun Sheng, , Shaohua Wang, , Shun Zhu, , Asiri Abdullah M. . Synthesis and Anti-inflammatory Effects of Oxaprozin-Paeonol Ester[J]. Chinese Journal of Organic Chemistry, 2019 , 39(10) : 2958 -2964 . DOI: 10.6023/cjoc201903020

References

[1] Talaat, R.; El-Sayed, W.; Agwa, H. S.; Gamal-Eldeen, A. M.; Moawia, S.; Zahran, M. A. H. Chem.-Biol. Interact. 2015, 238, 74.
[2] McInnes, I. B.; Schett, G. Nat. Rev. Immunol. 2007, 7, 429.
[3] Shin, J. S.; Choi, H. E.; Kim, S. D.; Lee, Y. S.; Cho, Y. W.; Lee, K. T. Chem. Biol. Interact. 2014, 224, 68.
[4] Wu, J.; Chu, C. C. J. Mater. Chem. B 2013, 1, 353.
[5] Wu, J.; Chu, C. C. Acta Biomater. 2012, 8, 4314.
[6] Rao, P. P. N.; Kabir, S. N; Mohamed, T. Pharmaceuticals 2010, 3, 1530.
[7] Rainsford, K. D.; Whitehouse, M. W . Inflammopharmacology 2006, 14, 150.
[8] Robak, P.; Smolewski, P.; Robak, T . Leuk Lymphoma 2008, 49, 1452.
[9] Macario, A.; Lipman, A. G. Pain Med. 2001, 2, 336.
[10] al-Faks, M. A.; Pugh, M. C. Orthop. Rev. 1995, 21, 558.
[11] Bozic, B. D.; Rogan, J. R.; Poleti, D. D.; Trisovic, N. P.; Uscumlic, G. S. Chem. Pharm. Bull. 2012, 60, 865.
[12] Rainsford, K. D.; Omar, H.; Ashraf, A.; Hewson, A. T. R.; Bunning, A. D.; Rishiraj, R.; Shepherd, P.; Seabrook, R. W . Inflammopharmacology 2002, 10, 185.
[13] Lopes-de-Araújo, J.; Neves, A. R.; Gouveia, V. M.; Moura, C. C.; Nunes, C.; Reis, S . Pharm. Res. 2016, 33, 301.
[14] Peesa, J. P.; Atmakuri, L. R.; Yalavarthi, P. R.; Venkata, B. R. M.; Rasheed, A.; Pachava, V. Arch. Pharm. Chem. Life Sci. 2017, 351, e1700256.
[15] Dallegri, F.; Bertolotto, M.; Ottonello, L. Exp. Opin. Ther. 2005, 1, 777.
[16] Peesa, J. P.; Yalavarthi, P. R.; Rasheed, A.; Mandava, V. B. J. Acute Dis. 2016, 1, 364.
[17] Bandgar, B. P.; Sarangdhar, R. J.; Viswakarma, S.; Ahamed, F. A. J. Med. Chem., 2011, 1, 1191.
[18] Chou, T. C. Br. J. Pharmacol. 2003, 139, 1146.
[19] Huang, T. J.; Chuang, H.; Liang, Y. C.; Lin, H. H.; Horng, J. C.; Kuo, Y. C.; Chen, C. W.; Tsai, F. Y.; Yen, S. C.; Chou, S. C.; Hsu, M. H. Eur. J. Med. Chem. 2015, 90, 428.
[20] Nizamutdinova, I. T.; Jin, Y. C.; Kim, J. S.; Yean, M. H.; Kang, S. S.; Kim, Y. S.; Lee, J. H.; Seo, H. G.; Kim, H. J.; Chang, K. C. Planta Med. 2008, 74, 8.
[21] Huang, L.; Zhang, B.; Yang, Y.; Gong, X.; Chen, Z.; Wang, Z.; Zhang, P.; Zhang, Q. Bioorg. Med. Chem. Lett. 2016, 26, 5218.
[22] Zhang, H.; Chen, S.; Deng, X.; Yang, X.; Huang, X. Diabetes Res. Clin. Pract. 2006, 74, 194.
[23] Nizamutdinova, I. T.; Oh, H. M.; Min, Y. N.; Park, S. H.; Lee, M. J.; Kim, J. S.; Yean, M. H.; Kang, S. S.; Kim, Y. S.; Chang, K. C.; Kim, H. J. Int. Immunopharmacol. 2007, 7, 343.
[24] Jin, X.; Wang, J.; Xia, Z. M.; Shang, C. H.; Chao, Q. L.; Fan, H. Y.; Chen, D. Q.; Qiu, F.; Zhao, F . Inflammation 2016, 39, 434.
[25] Wu, P. P.; He, H.; Hong, W. D.; Wu, T.; Huang, G.; Zhong, Y.; Tu B.; Gao, M.; Zhou, J.; Zhao, S.; Li, D.; Xu, X. T.; Sheng, Z.; Ward, S. A.; O'Neill, P. M.; Zhang, K. Infect. Drug Resist. 2018, 11, 1945.
[26] Xu, L.; Mou, X. Q.; Chen, Z. M.; Wang, S. H. Chem. Commun. 2014, 50, 10676.
[27] Hernández, V.; Má?ez, S.; Recio, M. C.; Giner, R. M.; Ríos, J. L. Eur. J. Pharm. Sci., 2005, 26, 162.
[28] Mehrotra, A.; Shanbhag, R.; Chamallamudi, M. R.; Singh, V. P.; Mudgal, J. Eur. J. Pharm. 2011, 666, 80.
[29] Hernández, I.; Márquez, L.; Martínez, I.; Dieguez, R.; Delporte, C.; Prieto, S.; Molina-Torres, J.; Garrido, G. J . Ethnopharmacol. 2009, 124, 649.
[30] Xu, X. T.; Mou, X. Q.; Xi, Q. M.; Liu, W. T.; Liu, W. F.; Sheng, Z. J.; Zheng, X.; Zhang, K.; Du, Z. Y.; Zhao, S. Q.; Wang, S. H. Bioorg. Med. Chem. Lett. 2016, 26, 5334.
[31] Xu, X. T.; Huang, D. Y.; Liu, W. F.; Sheng, Z. J.; Liang, K. Y.; Li, D. L.; Zhao, D.; Ma, Y.; Zhang, K.; Hayat, T.; Alharbif, N. S.; Li, W. K. RSC Adv., 2017, 7, 34699.
[32] Rao, T. S.; Currie, J. L.; Shaffer, A. F.; Isakson, P. C . Inflammation 1993, 17, 723.
[33] Hauser, C.; Dayer, J. M.; Jaunin, F.; de Rochemonteix, B.; Saurat, J. H. Cell. Immunol. 1986, 100, 89.
[34] Kock, A.; Schwarz, T.; Kirnbauer, R.; Urbanski, A.; Perry, P.; Ansel, J. C.; Luger, T. A. J. Exp. Med. 1990, 172, 1609.
[35] Kupper, T. S.; Ballard, D. W.; Chua, A. O.; McGuire, J. S.; Flood, P. M.; Horowitz, M. C.; Langdon, R.; Lightfoot, L.; Gubler, U. J. Exp. Med. 1986, 164, 2095.
[36] Singh, S.; Aggarwal, B. B. J. Biol. Chem. 1995, 270, 10631.
[37] Han, S. S.; Keum, Y. S.; Seo, H. J.; Chun, K. S.; Lee, S. S.; Surh, Y. J. Cancer Lett. 2001, 164, 119.
[38] Kim, S. O.; Kundu, J. K.; Shin, Y. K.; Park, J. H.; Cho, M. H.; Kim, T. Y.; Surh, Y. J . Oncogene 2005, 24, 2558.
[39] Zandi, E.; Rothwarf, D. M.; Delhase, M.; Hayakawa, M.; Karin, M . Cell 1997, 91, 243.
[40] Li, Z. W.; Chu, W.; Hu, Y.; Delhase, M.; Deerinck, T.; Ellisman, M.; Johnson, R.; Karin, M. J. Exp. Med. 1999, 189, 1839.
[41] Karin, M.; Delhase, M . Semin. Immunol. 2000, 12, 85.
[42] Carpenter, C. L.; Cantley, L. C. Curr. Opin. Cell Biol. 1996, 8, 153.
[43] Karin, M . Oncogene 1999, 18, 6867.
[44] Shimamura, H.; Terada, Y.; Okado, T.; Hiroyuki, T.; Inoshita, S.; Sadak, S. J. Am. Soc. Nephrol. 2003, 14, 1427.
[45] Selvaraj, S. K.; Giri, R. K.; Perelman, N.; Johnson, C.; Malik, P.; Kalra, V. K . Blood 2003, 102, 1515.
[46] Hatcher, H.; Planalp, R.; Cho, J.; Torti, F. M.; Torti, S. V. Cell. Mol. Life Sci. 2008, 65, 1631.
[47] V. Stefano, D. M. Paolo, S. Rossana and L. Luisa , J. Drugs Dermatol. 2009, 8, 537.
[48] Liu, W. F.; Li, Y. L.; Zhang, K.; Du, Z. Y. Food Funct. 2015, 6, 3712.
[49] Liu, W. F.; Li, Y. L.; Zheng, X.; Zhang, K.; Du, Z. Med. Chem. Commun. 2015, 6, 1605.
[50] Liu, W. F.; Li, Y. L.; Yue, Y.; Zhang, K.; Chen, Q.; Wang, H. Q.; Lu, Y. J.; Huang, M. T.; Zheng, X.; Du, Z. Y. Bioorg. Med. Chem. Lett. 2015, 25, 3044.
[51] Kraan, M. C.; Haringman, J. J.; Ahern, M. J.; Breedveld, F. C.; Smith, M. D.; Tak, P. P . Rheumatology 2000, 39, 43.
[52] Ouyang, N.; Williams, J. L.; Tsioulias, G. J.; Gao, J. J.; Iatropoulos, M. J.; Kopelovich, L.; Kashfi, K.; Rigas, B . Cancer Res. 2006, 66, 4503.
Options
Outlines

/

〈 〉